Galectin Therapeutics (GALT) Misses Q3 EPS by 14c

Galectin Therapeutics (NASDAQ: GALT) reported Q3 EPS of ($0.24), $0.14 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO starts chip stocks coverage: Here are its preferred picks
• Is the global equity rally broadening? UBS weighs in